Prelude Therapeutics (PRLD) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 166.0% versus a loss of 18.3%. Over five years, PRLD leads with a -76.4% price change compared with -98.2% for XFOR. Prelude Therapeutics is the larger company by market cap ($305.6 million vs $278.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | XFOR |
|---|---|---|
| Share price | $3.83 | $2.81 |
| Market cap | $305.65M | $278.60M |
| 1-day change | +0.52% | +1.44% |
| YTD return | +32.07% | -29.75% |
| 1-year return | +165.97% | -18.31% |
| 5-year return | -76.45% | -98.21% |
| P/E ratio (TTM) | — | 140.50 |
| EPS (TTM) | $-0.73 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.83 | $4.83 |
| 52-week low | $1.15 | $2.70 |
| Distance from 52-week high | -43.92% | -41.82% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +140.21% | +312.81% |
| Average volume | 477.81K | 849.98K |
| Shares outstanding | 65.08M | 99.15M |
| Employees | 79 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed XFOR by 184.3 percentage points over the past year.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
PRLD vs XFOR FAQ
Which is bigger, Prelude Therapeutics or X4 Pharmaceuticals?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $305.65M compared with $278.60M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, PRLD or XFOR?
PRLD returned +165.97% over the past 12 months, compared with -18.31% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are Prelude Therapeutics and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Prelude Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.